Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 29Paclitaxel 7Magnetic Resonance Spectroscopy 7Cisplatin 7Pemetrexed 6Docetaxel 6Carboplatin 6Standard of Care 5Radiotherapy 5Nivolumab 5Drug Therapy 5Specimen Handling 4Gemcitabine 4Cetuximab 4Blood Specimen Collection 4epacadostat 3X-Rays 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Oncolytic Virotherapy 3Nicotine 3Fluorouracil 3Filgrastim 3Cyclophosphamide 3Bupropion 3Bortezomib 3Biopsy 3spartalizumab 2selpercatinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × parsaclisib × Head & Neck × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡